Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell ...

If patients with breast cancer hyperglycemia or symptoms of it at home, a short break from capivasertib may be required, according to Hope Rugo, MD.

New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.